Overview

Compare the Renal Protective Effects of Febuxostat and Benzbromarone in CKD Chinese Patients

Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to determine whether febuxostat and benzbromarone could protect renal function in chinese, and which one could be better.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Shanghai 10th People's Hospital
Treatments:
Benzbromarone
Febuxostat
Criteria
Inclusion Criteria:

Chronic kidney disease patients with glomerular filtration rate (GFR,20-60ml/min) who match
one of the following criteria:

1. Gout

2. serum uric acid > 480umol/L

Exclusion Criteria:

1. GFR<20ml/min or GFR >60ml/min

2. Liver dysfunction (Aspartate transaminase or/and alanine aminotransferase exceed 2
times of normal range)

3. Urinary tract obstruction

4. unstable angina, heart failure (stage III-IV, NYHA), new stroke, need diuretics for
long-term treatment

5. Severe lung diseases or cancers

6. Pregnant woman or woman who prepare to be pregnant,nursing mothers

7. unable to sign informed consent form,or disagree with following-up